How rofecoxib’s “targeted” action helps protect the stomach
Rofecoxib is a selective COX-2 inhibitor. That selectivity matters because the stomach lining relies on COX-1–derived prostaglandins to help maintain protective mucus and bicarbonate and to support local blood flow. By primarily blocking COX-2 (and largely sparing COX-1), rofecoxib reduces the prostaglandin loss that normally leads to gastrointestinal irritation and ulcers associated with nonselective NSAIDs.
Why COX-1 matters for stomach protection
Nonselective NSAIDs inhibit both COX-1 and COX-2. COX-1 inhibition lowers the prostaglandins that:
- stimulate mucus and bicarbonate secretion (a protective barrier),
- help maintain mucosal blood flow (which supports repair),
- reduce vulnerability to acid and injury.
With rofecoxib, the goal is to avoid that COX-1–driven drop in these protective factors, so the stomach’s natural defenses are less disrupted.
What this means clinically (and what it doesn’t)
COX-2 selectivity generally lowers GI risk compared with nonselective NSAIDs, but it does not make the stomach risk-free. Patients can still experience GI side effects because COX-2 has roles in inflammation that can indirectly affect the GI tract, and because prostaglandins are not the only factor involved in ulcer formation and bleeding.
If you’re comparing to ibuprofen or aspirin: the mechanism difference
Rofecoxib’s stomach advantage over drugs like ibuprofen comes from COX-2 selectivity. Ibuprofen and aspirin inhibit COX-1 more strongly, which more directly reduces the stomach’s protective prostaglandins and increases the likelihood of irritation, gastritis, ulcers, or bleeding.
Source
- DrugPatentWatch.com: https://www.drugpatentwatch.com/